Full integration of centralized data management platform with market leading software applications provides unique end-to-end biology solution for antibody discovery

Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, announce the release of its Biology Solution for Antibody Discovery, a unique end-to-end software and data management package. The antibody workflow combines Dotmatics’ enterprise scientific platform with advanced applications software used routinely in antibody discovery laboratories including Geneious, SnapGene, and GraphPad Prism. The fully integrated solution will streamline data collection and processing of the antibody discovery workflow, facilitating a pathway to more effective and efficient discovery, and accelerating progress towards potentially life-changing therapies for patients.

“The launch of the Dotmatics Biology Solution for Antibody Discovery is the industry’s first true end-to-end solution for antibody workflows and represents a huge step forward for innovation in antibody discovery,” said Mike McKee, president of Dotmatics. “Whether it’s R&D for biology or chemistry or formulations, Dotmatics helps scientists and their organizations harmonize data science with the science data.”

Finding research data across a siloed enterprise and local systems remains a critical challenge for drug discovery researchers. Scientists are forced to compromise either speed or accuracy. With many disconnected workflows the outcome is often manual data handling, leading to risks of data errors and inefficiencies.

Dotmatics antibody workflow supports the breadth of antibody discovery by addressing these issues, giving organizations a cloud-based data management platform that is centralized and fully integrated with proven scientific applications and productivity tools that end-users trust. Critically, it automates manual, error-prone data tasks and centralizes data management helping organizations make smarter decisions and ultimately accelerating antibody research.

Growth in antibody research for the purpose of fighting chronic diseases with antibody therapies is highlighted by the projected investment in the market. A 2022 research report by Future Market Insights projected that the antibody therapy market is expected to reach $700 billion by 2032, up from $186 billion. Another report by the Insight Partners projects that the global monoclonal antibody market will reach $243 billion by 2028 from $111 billion in 2021.

“As scientists pursue critical antibody therapies to fight disease, Dotmatics is connecting them with their data in ways that accelerate innovation and help make the world a healthier, cleaner, safer place to live,” said Michael Swartz, senior vice president of enterprise product at Dotmatics. “We are at the forefront of a digital transformation in the scientific R&D industry with an emphasis on providing researchers end-to-end solutions with connected data and workflows. They should be able to use the tools they know and love, while still centralizing data in order to satisfy the needs of the organization.”  

The Dotmatics antibody workflow incorporates FAIR data practices and provides a uniquely broad and deep solution traversing early candidate selection through cycles of innovation to provide highly refined antibody candidates to progress into animal trial and translational medicine.

About Dotmatics

Dotmatics is a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and scientists’ favorite applications drive efficiency and accelerate innovation. More than 2 million scientists and 10,000 customers trust Dotmatics to help them create a healthier, cleaner, safer world. Dotmatics is a global team of more than 800 employees dedicated to supporting its customers in over 180 countries. The company’s principal office isin Boston, with 14 offices and R&D teams located around the world.

Dotmatics is backed by Insight Partners, a leading global venture capital and private equity firm investing in high-growth technology and software scaleup companies.